A vanishing act: the incredible erlotinib

J Cancer Res Ther. Jul-Sep 2012;8(3):464. doi: 10.4103/0973-1482.103539.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Cisplatin / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • ErbB Receptors / genetics*
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Mutation
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quinazolines / adverse effects*
  • Quinazolines / therapeutic use*
  • Smoking

Substances

  • Quinazolines
  • Deoxycytidine
  • gemcitabine
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Cisplatin